Viridian Therapeutics
VRDN
8 hedge funds and large institutions have $287K invested in Viridian Therapeutics in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
16% less capital invested
Capital invested by funds: $341K → $287K (-$54K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$56.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.1K |
| 3 |
PCM
Prelude Capital Management
New York
|
+$17.4K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.42K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$25K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
HighTower Advisors
Chicago,
Illinois
| $158K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $53K | +$25.1K | +240 | +53% |
|
|
3
Renaissance Technologies
New York
| $53K | +$56.2K | +538 | +320% |
|
|
PCM
4
Prelude Capital Management
New York
| $13K | +$17.4K | +167 | New |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $5K | +$7.42K | +71 | New |
|
6
Creative Planning
Overland Park,
Kansas
| $3K | – | – | – |
|
|
BFA
7
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$104 | +1 | +14% |
|
|
8
Acadian Asset Management
Boston,
Massachusetts
| $1K | +$1.57K | +15 | New |
|
|
PCM
9
Perkins Capital Management
Wayzata,
Minnesota
| – | -$25K | -218 | Closed |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$5K | -45 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$1K | -9 | Closed |
|
VRDN Hedge Fund Activity: Q4 2016 in Review
8 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2016, worth a combined $287K — down 16% from $341K a quarter earlier.
Fund positioning in VRDN was balanced in Q4 2016: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $56.2K. The largest seller was Perkins Capital Management, exiting entirely with an estimated $25K sold.
- 8 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $287K of Viridian Therapeutics stock for Q4 2016, down 16% quarter-over-quarter.
- 3 funds opened new Viridian Therapeutics positions in Q4 2016 and 3 closed out, a net change of 0 holders.
- The largest Viridian Therapeutics buyer in Q4 2016 was Renaissance Technologies, an estimated $56.2K added.
- The largest Viridian Therapeutics seller in Q4 2016 was Perkins Capital Management, an estimated $25K sold.
Based on aggregated 13F filings for Q4 2016.